TY - JOUR AB - Ovarian cancer is the most lethal gynecologic malignancy, and ovarian cancer stem cells (CSCs) serve a pivotal function in the metastasis and recurrence of ovarian cancer. Multiple previous studies have validated CD133 as a marker of ovarian CSCs. Although salinomycin is a promising therapeutic agent that has been demonstrated to kill CSCs in various types of cancer, poor aqueous solubility hampers its clinical application. The present study used salinomycin‑loaded poly(lactic‑co‑glycolic acid)‑poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133‑SAL‑NP) to eliminate CD133+ ovarian CSCs. The results revealed that CD133‑SAL‑NPs were of an appropriate size (149.2 nm) and exhibited sustained drug release. CD133‑SAL‑NPs efficiently bound to CD133+ ovarian cancer cells, resulting in an increased cytotoxic effect in CD133+ ovarian cancer cells, compared with the untargeted SAL‑NPs and salinomycin. CD133‑SAL‑NPs reduced the percentage of CD133+ ovarian CSCs in ovarian cells more effectively than treatment with salinomycin or SAL‑NPs, suggesting that CD133‑SAL‑NP targeted CD133+ ovarian CSCs. In nude mice bearing ovarian cancer xenografts, CD133‑SAL‑NPs exerted improved therapeutic effects compared with SAL‑NPs and salinomycin. Thus, CD133 was demonstrated to be a promising target for drug delivery to ovarian CSCs, and may be useful as an agent to inhibit the growth of ovarian cancer by targeting CD133+ ovarian CSCs. CD133‑SAL‑NPs may therefore represent a promising approach for the treatment of ovarian cancer. AD - Department of Obstetrics and Gynecology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China AU - Mi,Yi AU - Huang,Yuqin AU - Deng,Jie DA - 2018/05/01 DO - 10.3892/ol.2018.8140 EP - 6621 IS - 5 JO - Oncol Lett KW - nanomedicines ovarian cancer cancer stem cells salinomycin cluster of differentiation 133 PY - 2018 SN - 1792-1074 1792-1082 SP - 6611 ST - The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles T2 - Oncology Letters TI - The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles UR - https://doi.org/10.3892/ol.2018.8140 VL - 15 ER -